Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2018 | 46 | 2.160 |
Why?
|
| Alzheimer Disease | 7 | 2022 | 30 | 1.830 |
Why?
|
| Inpatients | 3 | 2020 | 22 | 1.160 |
Why?
|
| Dementia | 3 | 2018 | 14 | 1.080 |
Why?
|
| Insulin Resistance | 2 | 2021 | 74 | 0.680 |
Why?
|
| Hospitalization | 3 | 2018 | 128 | 0.670 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2020 | 3 | 0.640 |
Why?
|
| Aged | 13 | 2020 | 1539 | 0.630 |
Why?
|
| Humans | 22 | 2022 | 6794 | 0.610 |
Why?
|
| Neoplasms | 1 | 2020 | 92 | 0.580 |
Why?
|
| Cognition | 2 | 2021 | 30 | 0.580 |
Why?
|
| Life Style | 2 | 2022 | 51 | 0.550 |
Why?
|
| Male | 16 | 2021 | 3671 | 0.540 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 15 | 0.530 |
Why?
|
| Female | 17 | 2021 | 4060 | 0.530 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 497 | 0.510 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 12 | 0.490 |
Why?
|
| Seizures | 1 | 2014 | 16 | 0.420 |
Why?
|
| Risk Factors | 6 | 2022 | 767 | 0.410 |
Why?
|
| United States | 7 | 2020 | 1019 | 0.400 |
Why?
|
| Hypertension | 5 | 2018 | 147 | 0.390 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2012 | 7 | 0.380 |
Why?
|
| Atrial Fibrillation | 3 | 2016 | 16 | 0.350 |
Why?
|
| Diet | 1 | 2012 | 111 | 0.340 |
Why?
|
| Retrospective Studies | 4 | 2018 | 681 | 0.330 |
Why?
|
| Comorbidity | 5 | 2018 | 147 | 0.330 |
Why?
|
| Middle Aged | 10 | 2021 | 2108 | 0.310 |
Why?
|
| Communication | 2 | 2021 | 31 | 0.280 |
Why?
|
| Databases, Factual | 2 | 2020 | 81 | 0.270 |
Why?
|
| Prevalence | 3 | 2018 | 259 | 0.260 |
Why?
|
| Leisure Activities | 2 | 2017 | 6 | 0.250 |
Why?
|
| Exercise | 2 | 2017 | 55 | 0.230 |
Why?
|
| Hospital Mortality | 2 | 2015 | 36 | 0.230 |
Why?
|
| Algorithms | 2 | 2016 | 83 | 0.190 |
Why?
|
| Amyloid | 1 | 2021 | 3 | 0.180 |
Why?
|
| Retinal Vein | 1 | 2021 | 3 | 0.180 |
Why?
|
| Memory Disorders | 1 | 2021 | 6 | 0.180 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 169 | 0.180 |
Why?
|
| Dysbiosis | 1 | 2021 | 10 | 0.170 |
Why?
|
| Logistic Models | 2 | 2018 | 165 | 0.160 |
Why?
|
| Length of Stay | 1 | 2020 | 53 | 0.160 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 15 | 0.150 |
Why?
|
| Amnesia, Transient Global | 1 | 2018 | 3 | 0.150 |
Why?
|
| Time Factors | 2 | 2018 | 321 | 0.140 |
Why?
|
| Migraine Disorders | 1 | 2018 | 10 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 8 | 0.140 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 22 | 0.140 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 5 | 0.140 |
Why?
|
| Brain Ischemia | 1 | 2018 | 10 | 0.140 |
Why?
|
| Brain | 2 | 2021 | 94 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 82 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 279 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 67 | 0.130 |
Why?
|
| Health Surveys | 1 | 2017 | 75 | 0.130 |
Why?
|
| Incidence | 2 | 2017 | 197 | 0.130 |
Why?
|
| Sex Factors | 1 | 2018 | 155 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 208 | 0.120 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 2 | 0.120 |
Why?
|
| Angina, Unstable | 1 | 2016 | 5 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 42 | 0.120 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 11 | 0.120 |
Why?
|
| Dementia, Vascular | 1 | 2016 | 6 | 0.120 |
Why?
|
| Heart Failure | 1 | 2016 | 49 | 0.120 |
Why?
|
| Hypesthesia | 1 | 2015 | 1 | 0.120 |
Why?
|
| Face | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 506 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2015 | 16 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2015 | 22 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 118 | 0.110 |
Why?
|
| Mortality | 1 | 2015 | 43 | 0.110 |
Why?
|
| Health Behavior | 1 | 2015 | 65 | 0.110 |
Why?
|
| Women | 1 | 2014 | 4 | 0.110 |
Why?
|
| Community Health Workers | 1 | 2014 | 13 | 0.110 |
Why?
|
| Social Networking | 1 | 2014 | 11 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2015 | 145 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 71 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 140 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 193 | 0.100 |
Why?
|
| Lewy Body Disease | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 172 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2012 | 38 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 64 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 293 | 0.090 |
Why?
|
| Adult | 4 | 2018 | 2113 | 0.080 |
Why?
|
| Evoked Potentials | 1 | 2009 | 2 | 0.080 |
Why?
|
| Nerve Net | 1 | 2009 | 3 | 0.080 |
Why?
|
| Task Performance and Analysis | 1 | 2009 | 4 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 6 | 0.080 |
Why?
|
| Temporal Lobe | 1 | 2008 | 4 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 9 | 0.070 |
Why?
|
| Oxygen | 1 | 2008 | 44 | 0.070 |
Why?
|
| Antiparkinson Agents | 1 | 2003 | 1 | 0.050 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2003 | 1 | 0.050 |
Why?
|
| Purines | 1 | 2003 | 10 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2003 | 6 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 43 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2015 | 197 | 0.040 |
Why?
|
| Amyloid beta-Peptides | 1 | 2021 | 5 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 89 | 0.040 |
Why?
|
| American Heart Association | 1 | 2017 | 1 | 0.030 |
Why?
|
| School Teachers | 1 | 2017 | 2 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 18 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 104 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 35 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 268 | 0.030 |
Why?
|
| California | 1 | 2017 | 230 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 280 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 8 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 44 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 82 | 0.030 |
Why?
|
| Women's Rights | 1 | 2014 | 3 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 128 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 65 | 0.030 |
Why?
|
| Smoking | 1 | 2015 | 86 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 34 | 0.030 |
Why?
|
| Women's Health | 1 | 2014 | 24 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 197 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2015 | 331 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 3 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 10 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 226 | 0.020 |
Why?
|
| African Americans | 1 | 2015 | 264 | 0.020 |
Why?
|
| Rest | 1 | 2009 | 1 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2009 | 6 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 79 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 98 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 112 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Family Health | 1 | 2008 | 8 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 15 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 41 | 0.020 |
Why?
|
| Carbidopa | 1 | 2003 | 1 | 0.010 |
Why?
|
| Levodopa | 1 | 2003 | 1 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 26 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 18 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 54 | 0.010 |
Why?
|
| Motor Activity | 1 | 2003 | 26 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 101 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 155 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 500 | 0.010 |
Why?
|